186 related articles for article (PubMed ID: 37481734)
1. Biomimetic Mineralized CRISPR/Cas RNA Nanoparticles for Efficient Tumor-Specific Multiplex Gene Editing.
Liang Y; Zhang J; Xu C; Wang J; Han W; Yang J; Wu S; An J; Liu J; Zhang Z; Shi J; Zhang K
ACS Nano; 2023 Aug; 17(15):15025-15043. PubMed ID: 37481734
[TBL] [Abstract][Full Text] [Related]
2. CES1-Triggered Liver-Specific Cargo Release of CRISPR/Cas9 Elements by Cationic Triadic Copolymeric Nanoparticles Targeting Gene Editing of PCSK9 for Hyperlipidemia Amelioration.
Zhao Y; Li Y; Wang F; Gan X; Zheng T; Chen M; Wei L; Chen J; Yu C
Adv Sci (Weinh); 2023 Jul; 10(19):e2300502. PubMed ID: 37083231
[TBL] [Abstract][Full Text] [Related]
3. Biomimetic Mineralization-Based CRISPR/Cas9 Ribonucleoprotein Nanoparticles for Gene Editing.
Li S; Song Z; Liu C; Chen XL; Han H
ACS Appl Mater Interfaces; 2019 Dec; 11(51):47762-47770. PubMed ID: 31773942
[TBL] [Abstract][Full Text] [Related]
4. Development of ionizable lipid nanoparticles and a lyophilized formulation for potent CRISPR-Cas9 delivery and genome editing.
Sun Q; Zhang H; Ding F; Gao X; Zhu Z; Yang C
Int J Pharm; 2024 Mar; 652():123845. PubMed ID: 38266942
[TBL] [Abstract][Full Text] [Related]
5. Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA.
Miller JB; Zhang S; Kos P; Xiong H; Zhou K; Perelman SS; Zhu H; Siegwart DJ
Angew Chem Int Ed Engl; 2017 Jan; 56(4):1059-1063. PubMed ID: 27981708
[TBL] [Abstract][Full Text] [Related]
6. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
[TBL] [Abstract][Full Text] [Related]
7. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
[TBL] [Abstract][Full Text] [Related]
8. A quaternary ammonium-based nanosystem enables delivery of CRISPR/Cas9 for cancer therapy.
Zhang M; Sun S; Liang X; Liu Z; Yin J; Li Q; Yang S
Biomater Sci; 2024 Feb; 12(5):1197-1210. PubMed ID: 38240497
[TBL] [Abstract][Full Text] [Related]
9. Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide.
Wang HX; Song Z; Lao YH; Xu X; Gong J; Cheng D; Chakraborty S; Park JS; Li M; Huang D; Yin L; Cheng J; Leong KW
Proc Natl Acad Sci U S A; 2018 May; 115(19):4903-4908. PubMed ID: 29686087
[TBL] [Abstract][Full Text] [Related]
10. Biomaterial-assisted targeted and controlled delivery of CRISPR/Cas9 for precise gene editing.
Iqbal Z; Rehman K; Xia J; Shabbir M; Zaman M; Liang Y; Duan L
Biomater Sci; 2023 May; 11(11):3762-3783. PubMed ID: 37102700
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.
Zhang BC; Luo BY; Zou JJ; Wu PY; Jiang JL; Le JQ; Zhao RR; Chen L; Shao JW
ACS Appl Mater Interfaces; 2020 Dec; 12(51):57362-57372. PubMed ID: 33301289
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.
Givens BE; Naguib YW; Geary SM; Devor EJ; Salem AK
AAPS J; 2018 Oct; 20(6):108. PubMed ID: 30306365
[TBL] [Abstract][Full Text] [Related]
13. Latest progress in the study of nanoparticle-based delivery of the CRISPR/Cas9 system.
Yu M; Liu X; Cheng H; Kuang L; Zhang S; Yan X
Methods; 2021 Oct; 194():48-55. PubMed ID: 34107351
[TBL] [Abstract][Full Text] [Related]
14. Biomimetic gene editing system for precise tumor cell reprogramming and augmented tumor therapy.
Qiao L; Gao M; Yi X; Peng H; Zhang R; Yao W; Sun G; He X
J Control Release; 2023 Apr; 356():663-677. PubMed ID: 36924897
[TBL] [Abstract][Full Text] [Related]
15. Near-infrared upconversion-activated CRISPR-Cas9 system: A remote-controlled gene editing platform.
Pan Y; Yang J; Luan X; Liu X; Li X; Yang J; Huang T; Sun L; Wang Y; Lin Y; Song Y
Sci Adv; 2019 Apr; 5(4):eaav7199. PubMed ID: 30949579
[TBL] [Abstract][Full Text] [Related]
16. Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid.
Tang Q; Liu J; Jiang Y; Zhang M; Mao L; Wang M
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46585-46590. PubMed ID: 31763806
[TBL] [Abstract][Full Text] [Related]
17. Construction of a One-Vector Multiplex CRISPR/Cas9 Editing System to Inhibit Nucleopolyhedrovirus Replication in Silkworms.
Dong Z; Qin Q; Hu Z; Chen P; Huang L; Zhang X; Tian T; Lu C; Pan M
Virol Sin; 2019 Aug; 34(4):444-453. PubMed ID: 31218589
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy.
Wang D; Chen L; Li C; Long Q; Yang Q; Huang A; Tang H
J Nanobiotechnology; 2022 Jan; 20(1):27. PubMed ID: 34991617
[TBL] [Abstract][Full Text] [Related]
19. Brain-targeted CRISPR/Cas9 nanomedicine for effective glioblastoma therapy.
Ruan W; Jiao M; Xu S; Ismail M; Xie X; An Y; Guo H; Qian R; Shi B; Zheng M
J Control Release; 2022 Nov; 351():739-751. PubMed ID: 36174804
[TBL] [Abstract][Full Text] [Related]
20. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
